COMPARISON
Carfilzomib vs KPV
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Carfilzomib is authorised or registered in 10 and KPV in 0 of the 10 registers read. Carfilzomib: highest phase Phase 3 (14 phase 3 trials, 0 with posted results). KPV: No trial states a phase. 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Carfilzomib | KPV | |
|---|---|---|
| Registered trials differs | 308 clinicaltrials.gov · 2026-10-03 | 4 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: KYPROLIS openfda · 2026-10-03T17:23:44.062Z | Not checked no record of "fdaLabel" for kpv |
| EU authorisation differs | Authorised ema · 2026-10-03 | Nothing on record ema read 2026-08-31 |
| EU authorised on differs | 2015-11-19 ema · 2026-10-03 | Not checked no record of "authorisedOn" for kpv |
| ATC code differs | L01XX45 ema · 2026-10-03 | Not checked no record of "atcCode" for kpv |
LEGAL STATUS
Approval in each country read
| Country | Carfilzomib | KPV | Register |
|---|---|---|---|
| United States | FDA-approved | Not on the register | Regulator FDA |
| European Union | Authorised | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Not on the register | Regulator MHRA |
| Canada | Authorised | Not on the register | Regulator Health Canada |
| Australia | Registered | Status unknown | Regulator TGA |
| Switzerland | Authorised | Not on the register | Regulator Swissmedic |
| Brazil | Registado | Not on the register | Regulator ANVISA |
| Serbia | Authorised | Not on the register | Regulator ALIMS |
| Singapore | Registered | Not on the register | Regulator HSA |
| Turkey | Ruhsatli | Not on the register | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.